Cancer immunotherapy has transformed the treatment landscape across multiple malignancies, offering durable responses and long-term survival for patients who previously had limited therapeutic options. Yet, as these therapies continue to reshape oncology, they also introduce one of the field’s most complex clinical challenges: harnessing the immune system without allowing it to turn against the patient.
In this Med News Week episode, Dr. Elad Sharon, Clinical and Translational Director of the Immunotherapy Toxicity Program at Dana-Farber Cancer Institute and Associate Professor of Medicine at Harvard Medical School, explores this delicate balance through the lens of both clinical practice and translational research.
Drawing on his extensive experience in immunotherapy drug development and immune-related adverse events (irAEs), Dr. Sharon examines how immune checkpoint inhibitors have revolutionized cancer care while simultaneously creating new questions surrounding toxicity, patient selection, and long-term management. His presentation illustrates why understanding the immune system has become just as important as understanding the tumor itself.
The discussion extends beyond the fundamentals of checkpoint inhibition to address some of oncology’s most pressing clinical dilemmas. Dr. Sharon shares insights into treating patients with pre-existing autoimmune diseases, organ transplants, HIV, tuberculosis risk, and pregnancy, populations that have historically been underrepresented in clinical trials but increasingly require evidence-based therapeutic strategies.
Rather than viewing immune-related toxicities solely as treatment complications, Dr. Sharon presents a compelling perspective: these adverse events may also provide valuable biological insights into autoimmunity, treatment response, and future biomarker development. The conversation highlights how translational research is helping clinicians better predict, prevent, and manage these toxicities while preserving the life-saving benefits of immunotherapy.
During the live Q&A session, Dr. Sharon offers thoughtful perspectives on emerging research directions, unanswered clinical questions, and the challenges that continue to shape modern immuno-oncology. He also reflects on the personal experiences that inspired his career, the importance of compassionate patient care, and his vision for ensuring that advances in cancer treatment benefit every patient—including those often excluded from traditional research.
This conversation offers valuable insights for oncologists, researchers, trainees, and anyone interested in the rapidly evolving intersection of cancer immunotherapy, translational science, and autoimmune disease.
Watch the full Med News Week episode to hear Dr. Elad Sharon‘s complete presentation and in-depth discussion on the future of immunotherapy, immune-related adverse events, and the next generation of cancer research.